S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
New AI Stock Payouts (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Options Trading Plan–Perfect For Beginners (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Options Trading Plan–Perfect For Beginners (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
New AI Stock Payouts (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Options Trading Plan–Perfect For Beginners (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Options Trading Plan–Perfect For Beginners (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
New AI Stock Payouts (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Options Trading Plan–Perfect For Beginners (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Options Trading Plan–Perfect For Beginners (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
New AI Stock Payouts (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Options Trading Plan–Perfect For Beginners (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Options Trading Plan–Perfect For Beginners (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price & News

$55.50
+2.40 (+4.52%)
(As of 09/26/2023 ET)
Compare
Today's Range
$52.43
$55.52
50-Day Range
$50.00
$61.26
52-Week Range
$6.93
$63.40
Volume
298,186 shs
Average Volume
457,753 shs
Market Capitalization
$3.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.80

MoonLake Immunotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
5.9% Upside
$58.80 Price Target
Short Interest
Healthy
16.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of MoonLake Immunotherapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$40 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.93) to ($1.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

825th out of 964 stocks

Biotechnology Industry

23rd out of 29 stocks


MLTX stock logo

About MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

MLTX Price History

MLTX Stock News Headlines

His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
These 8 Stocks Are Outperforming Nvidia In 2023
MoonLake Immunotherapeutics
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
MoonLake Immunotherapeutics (NASDAQ: MLTX)
MoonLake Immunotherapeutics (MLTX) Receives a Buy from LifeSci Capital
See More Headlines
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLTX Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MLTX
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$58.80
High Stock Price Forecast
$86.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+5.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-49,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.30 per share

Miscellaneous

Free Float
52,910,000
Market Cap
$3.47 billion
Optionable
Not Optionable
Beta
1.46
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Jorge Santos da Silva (Age 45)
    Co-Founder, CEO & Director
    Comp: $1.11M
  • Dr. Kristian Reich (Age 57)
    Co-Founder & Chief Scientific Officer
    Comp: $1.2M
  • Mr. Matthias Bodenstedt (Age 35)
    Chief Financial Officer
    Comp: $588.25k
  • Mr. Oliver Daltrop
    Chief Technical Officer
  • Nicolas Mosimann
    Gen. Counsel
  • Annett Zippel
    Director of People & Culture
  • Ms. Nuala Brennan
    Chief Clinical Devel. Officer













MLTX Stock - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MLTX shares.
View MLTX analyst ratings
or view top-rated stocks.

What is MoonLake Immunotherapeutics' stock price forecast for 2023?

10 Wall Street research analysts have issued 1 year target prices for MoonLake Immunotherapeutics' shares. Their MLTX share price forecasts range from $16.00 to $86.00. On average, they predict the company's stock price to reach $58.80 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts price targets for MLTX
or view top-rated stocks among Wall Street analysts.

How have MLTX shares performed in 2023?

MoonLake Immunotherapeutics' stock was trading at $10.50 at the start of the year. Since then, MLTX stock has increased by 428.6% and is now trading at $55.50.
View the best growth stocks for 2023 here
.

When is MoonLake Immunotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our MLTX earnings forecast
.

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04.

What is MoonLake Immunotherapeutics' stock symbol?

MoonLake Immunotherapeutics trades on the NASDAQ under the ticker symbol "MLTX."

Who are MoonLake Immunotherapeutics' major shareholders?

MoonLake Immunotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (15.45%), Citadel Advisors LLC (3.83%), Alliancebernstein L.P. (1.59%), Polar Capital Holdings Plc (1.40%), BlackRock Inc. (1.25%) and Banque Pictet & Cie SA (1.21%).
View institutional ownership trends
.

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MoonLake Immunotherapeutics' stock price today?

One share of MLTX stock can currently be purchased for approximately $55.50.

How much money does MoonLake Immunotherapeutics make?

MoonLake Immunotherapeutics (NASDAQ:MLTX) has a market capitalization of $3.47 billion. The company earns $-49,970,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How can I contact MoonLake Immunotherapeutics?

The official website for the company is www.moonlaketx.com. The company can be reached via phone at 41-41-510-8022 or via email at ir@moonlaketx.com.

This page (NASDAQ:MLTX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -